Becton, Dickinson and Company (NYSE:BDX) Shares Purchased by Glassman Wealth Services

Glassman Wealth Services raised its stake in Becton, Dickinson and Company (NYSE:BDX – Get Rating) by 6.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 808 shares of the medical instruments supplier’s stock after acquiring an additional 50 shares during the quarter. Glassman Wealth Services’ holdings in Becton, Dickinson and were worth $215,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in BDX. Two Sigma Advisers LP acquired a new position in shares of Becton, Dickinson and during the 3rd quarter worth approximately $4,744,000. Atria Investments LLC raised its stake in shares of Becton, Dickinson and by 2.6% during the 3rd quarter. Atria Investments LLC now owns 9,168 shares of the medical instruments supplier’s stock worth $2,254,000 after buying an additional 231 shares during the period. Laffer Tengler Investments purchased a new stake in shares of Becton, Dickinson and during the third quarter worth approximately $98,000. Cetera Advisor Networks LLC increased its position in shares of Becton, Dickinson and by 4.6% during the third quarter. Cetera Advisor Networks LLC now owns 14,139 shares of the medical instruments supplier’s stock worth $3,476,000 after purchasing an additional 619 shares in the last quarter. Finally, Cetera Advisors LLC increased its position in shares of Becton, Dickinson and by 9.5% during the third quarter. Cetera Advisors LLC now owns 7,596 shares of the medical instruments supplier’s stock worth $1,867,000 after purchasing an additional 656 shares in the last quarter. 86.58% of the stock is owned by institutional investors.

In other news, EVP David Hickey sold 475 shares of the stock in a transaction dated Friday, May 6th. The stock was sold at an average price of $256.00, for a total value of $121,600.00. Following the transaction, the executive vice president now owns 3,806 shares in the company, valued at approximately $974,336. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Thomas J. Spoerel sold 443 shares of the stock in a transaction dated Tuesday, June 7th. The shares were sold at an average price of $260.00, for a total value of $115,180.00. Following the completion of the transaction, the vice president now owns 1,058 shares in the company, valued at approximately $275,080. The disclosure for this sale can be found here. 0.50% of the stock is owned by company insiders.

Several analysts recently commented on BDX shares. StockNews.com cut Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Tuesday, June 14th. Morgan Stanley upped their price target on Becton, Dickinson and from $293.00 to $295.00 and gave the company an “overweight” rating in a research note on Monday, April 11th. Piper Sandler decreased their price target on Becton, Dickinson and from $265.00 to $255.00 in a research note on Thursday, May 5th. Argus upped their price target on Becton, Dickinson and from $275.00 to $310.00 in a research note on Monday, February 28th. Finally, Wells Fargo & Company upped their price target on Becton, Dickinson and from $275.00 to $285.00 and gave the company an “equal weight” rating in a research note on Friday, April 1st. Six research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, Becton, Dickinson and currently has a consensus rating of “Hold” and an average price target of $280.83.

BDX traded up $3.42 during mid-day trading on Thursday, hitting $240.69. 6,169 shares of the stock were exchanged, compared to its average volume of 992,629. The firm’s fifty day moving average is $252.17 and its two-hundred day moving average is $258.20. Becton, Dickinson and Company has a 1-year low of $231.46 and a 1-year high of $280.62. The company has a current ratio of 1.52, a quick ratio of 1.04 and a debt-to-equity ratio of 0.72. The company has a market cap of $68.61 billion, a PE ratio of 37.42, a PEG ratio of 3.20 and a beta of 0.64.

Becton, Dickinson and (NYSE:BDX – Get Rating) last posted its earnings results on Thursday, May 5th. The medical instruments supplier reported $3.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.98 by $0.20. Becton, Dickinson and had a return on equity of 14.91% and a net margin of 9.59%. The firm had revenue of $5.01 billion for the quarter, compared to analyst estimates of $4.78 billion. During the same quarter in the prior year, the company earned $3.19 EPS. Becton, Dickinson and’s revenue was up 2.1% on a year-over-year basis. As a group, research analysts anticipate that Becton, Dickinson and Company will post 11.2 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 30th. Investors of record on Thursday, June 9th will be paid a dividend of $0.87 per share. This represents a $3.48 annualized dividend and a yield of 1.45%. The ex-dividend date of this dividend is Wednesday, June 8th. Becton, Dickinson and’s payout ratio is 54.89%.

Becton, Dickinson and Profile (Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

See Also